February 2016 FDA Recall Drug by Astrazeneca Pharmaceuticals Lp
D-0781-2016 - Defective Delivery System

This Class II drug recall was voluntarily initiated by Astrazeneca Pharmaceuticals Lp on February 5, 2016 for the product Drug. The FDA reported the reason for recall as defective delivery system. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0781-2016

Reason for Recall
Defective Delivery System: Some units have actuation counters set to a number other than 60.
Initiated
02-05-2016
Reported
03-30-2016
Quantity
148,331 Inhalers

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
AstraZeneca Pharmaceuticals LP
US: Nationwide Including Puerto Rico
Tudorza Pressair (aclindinium bromide inhalation powder), 400 mcg per actuation, 60 Metered Doses per Inhaler, Rx Only. Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. Manufactured by: Forest Laboratories, Ireland Limited, Dublin 17 Ireland. Product of Spain. NDC: 0310-0800-60.

Batch or Lot Expiration Information

Lot# 1144394, Expiry: 04/2018
Lot# 1145539, Expiry: 04/2018
Lot# 1145868, Expiry: 05/2018.